By Stephen Priori, Director, ISPOR Publications

The ISPOR Best Contributed Podium and Poster Presentation Awards were established in 1998 to recognize the scientific merit of podium and poster presentations of the ISPOR Annual International Meetings, Annual European Congresses, and Asia-Pacific Conferences. At this year's European Congress, the ISPOR Awards Committee evaluated approximately 64 podium presentations and over 700 poster presentations.

Evaluations of scientific merit were based upon the following criteria:

• Background provides appropriate perspective / context for the subject
• Objectives / research questions are clearly stated
• Research design / methods / modeling is appropriate and transparent (scores on this will determine winners in case of ties)
• Data sources and/or sampling procedures are clear and appropriate
• Data analyses are appropriate
• Research objectives are met/addressed
• Implications of findings are discussed
• Factual information is kept separate from interpretations or implications
• Abstract is presented in an unbiased manner
• Clarity of presentation

THE RECIPIENTS  ARE: . . .

Best Contributed Paper Awards Podium Presentations

Best General Podium Presentations

ED3-DIFFERENCES IN HEALTH RELATED RESOURCE USE IN THE 6 MONTHS PRIOR TO AND AFTER INSULIN INITIATION IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND UK: DATA FROM THE INSTIGATE STUDY
Timlin L1, Tynan A1,Simpson A1, Jones S2, Liebl A3
1Eli Lilly and Company Limited, Surrey, UK, 2The James Cook University Hospital, Middlesborough, UK, 3Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany

ED4-THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINE VERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA
McEwan P1, Mehin N2, Tetlow AP3, Sharplin P3
1Cardiff University, Cardiff, South Glamorgan, UK, 2sanofi-aventis, Paris, France, 3Cardiff Research Consortium, Cardiff, South Glamorgan, UK

MC2-BAYESIAN MODELING OF RESOURCE USE ALONGSIDE ULTINATIONAL RANDOMISED CLINICAL TRIALS
Gauthier A1, Manca A2, Anton SF3, Dewberry H4
1i3 Innovus, Uxbridge, Middlesex, UK, 2University of York, York, UK, 3Boehringer-Ingelheim, Ridgefield, CT, USA, 4Boehringer Ingelheim Limited, Bracknell, Berkshire, UK

Best New Investigator Podium Presentations

RS3-IMPACT OF SOCIO-ECONOMIC FACTORS ON PATIENTS' KNOWLEDGE OF THEIR CONDITION, INVOLVEMENT IN TREATMENT DECISIONS AND THE SUBSEQUENT COMPLIANCE WITH THEIR TREATMENT REGIMEN
Palm M1, Higgins V2, Lawson R1, Piercy J3

PR7-PATIENT'S PREFERENCES FOR OSTEOPOROSIS DRUG TREATMENT: A DISCRETE CHOICE EXPERIMENT
De Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HAP, Koes BW, Steyerberg EW

Erasmus MC, Rotterdam, The Netherlands

PR8-EVALUATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE USING ORAL MESALAZINE ALONE OR IN COMBINATION WITH A MESALAZINE ENEMA IN ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMISED CONTROLLED TRIAL
Nielsen SK1, Currie CJ2, Connolly MP1, Bhatt A1

Best Student Podium Presentations

CN2-DEVELOPMENT AND VALIDATION OF OPTIMALLY WEIGHTED MEASURES OF GLOBAL HEALTH-RELATED QUALITY OF LIFE (QOL) AND UTILITY BASED ON A CANCER-SPECIFIC QOL INSTRUMENT
Grimison PS, Simes RJ, Stockler MR
NHMRC Clincial Trials Centre, University of Sydney, Camperdown, NSW, Australia

ES1 INCREMENTAL DIFFERENCES IN RESOURCE UTILIZATION AND COSTS OF TREATING PERSONS INFECTED WITH HIV IN A LOW SOCIOECONOMIC NEIGHBORHOOD
Johnston KM1, Levy A1, Lai C2, Briggs A3, Kerr T2, Montaner JS2, Tyndall M1
1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Centre for Excellence in HIV/AIDS Research, Vancouver, BC, Canada, 3University of Glasgow, Glasgow, UK

MC3-THE DEVELOPMENT OF AN INCREMENTAL WILLINGNESS TO PAY CURVE DERIVED FROM A DISCRETE CHOICE EXPERIMENT
Regier DA1, Marra CA2, Ryan M1
1University of Aberdeen, Aberdeen, Scotland, UK, 2University of British Columbia, Vancouver, BC, Canada

ISPOR Best Contributed Poster Presentation Awards

Best General Poster Presentations

PAR22-COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH ABATACEPT (ORENCIA) FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN THE UK
Lewis G1, Kielhorn A2, Diamantopoulos A3
1Roche Products Limited, Welwyn Garden City, Herts, UK, 2F. Hoffmann-La Roche AG, Basel, Switzerland, 3IMS Health, London, UK

PEY15- HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS IN FRANCE
Soubrane G1, Zlateva G2, Xu X3, Goss TF3, Buggage R2, Kosa M4
1Centre Hospitalier Intercommunal de Créteil, Créteil, France, 2Pfizer Inc, New York, NY, USA, 3Covance Market Access Services, Gaithersburg, MD, USA, 4Pfizer, Paris, France

POS8- COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID 5 MG FOR THE MANAGEMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN THE UK SETTING
Olson M1, Brereton N2, Huels J1, Roberts D3, Akehurst R2
1Novartis Pharma AG, Basel, Switzerland, 2University of Sheffield, Sheffield, UK, 3Novartis Pharmaceuticals UK Ltd, Frimley, UK

Best New Investigator Poster Presentations

PCN46-A COST UTILITY ANALYSIS OF MAINTENANCE RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR NON HODGKINS LYMPHOMA (NHL) IN THE UK
Geary U1, Lewis G2, Aultman R3, Aristides M4
1Roche Products Limited, Hertfordshire, UK, 2Roche Products Limited, Welwyn Garden City, Herts, UK, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4IMS Health, London, UK

PHP21- IMPACT OF DISCONTINUITY IN HEALTH INSURANCE ON RESOURCE UTILIZATION
Shah N, Banerjee R
Mayo Clinic, Rochester, MN, USA

POS14- COMPARISON OF SF-6D AND EQ-5D UTILITIES IN OSTEOPOROTIC HIP FRACTURE PATIENTS
Golicki D1, Latek MM2
1Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 2George Mason University, Fairfax, VA, USA

Best Student Poster Presentations

PIH9-ESTIMATION OF HEALTHCARE PROFESSIONALS' TIME INPUT USING MULTI-DIMENSIONAL WORK SAMPLING (MDWS)
Patterson SM1, Crealey GE2, Hughes CM1
1Queen's University Belfast, Belfast, Co. Antrim, UK, 2Clinical Research Support Centre, Belfast, Northern Ireland, UK

PMC2-A BAYESIAN ADAPTIVE DESIGN FOR EVALUATION OF THE GAP BETWEEN EFFICACY AND ERROR-ADJUSTED EFFECTIVENESS
Moriwaki K1, Kamae I2, Yanagisawa S1, Nagase H3
1Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, 2Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 3Kobe University School of Medicine, Kobe, Hyogo, Japan

PRS7-ANALYSIS OF THE PREDICTIVE ABILITY OF DIAGNOSTIC COST GROUPS, RXGROUPS, AND PRIOR COST FOR TEXAS MEDICAID COPD PATIENTS
Yarger SA, Rascati KL, Leslie RC
The University of Texas at Austin, Austin, TX, USA